Biotech News
Related news
ANABAnaptysBio, Inc.2026-09-21 20:15 EST
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
GNLXGenelux2026-08-13 20:20 EST
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
MGNXMacroGenics2026-08-13 20:05 EST
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
FATEFate Therapeutics2026-08-13 12:30 EST
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
LYELLyell Immunopharma2026-08-06 20:05 EST
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
RLAYRelay Therapeutics2026-08-06 20:05 EST
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
BMEABiomea Fusion2026-08-05 20:05 EST
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
ELVNEnliven Therapeutics2026-08-05 20:05 EST
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
RVMDRevolution Medicines2026-08-05 20:02 EST
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
NextCure
Oncology Drug Development NextCure develops novel therapies for cancer, with a pipeline that includes antibody-drug conjugates and immune-modulating approaches. SIM0505 SIM0505 is an antibody-drug conjugate targeting cadherin-6 and carrying a topoisomerase-1 inhibitor payload. It is being evaluated in tumors with elevated CDH6...
Recent company news
NXTCNextCure2026-08-06 20:01 EST
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
NXTCNextCure2026-07-14 10:00 EST
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
NXTCNextCure2026-06-04 12:00 EST
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
NXTCNextCure2026-06-01 12:00 EST
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
NXTCNextCure2026-05-07 20:05 EST
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
Stock data
- Close
- 4.96 USD
- Market cap
- 12.28M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States